| InP/010/18 | Testing Ivabradine On Patient Derived Xenografts: A Novel Potential Targeted Treatment For Breast Cancer | 126440 | 2016 |
| InP/025/17 | Testing Ivabradine On Patient Derived Xenografts: A Novel Potential Targeted Treatment For Breast Cancer | 303497 | 2016 |
| HKU 767307M | Splicing variant profiling in relation to Estrogen Receptor gene expression in Chinese breast cancer | 882627 | 2007 |
| 04050252 | Promoter polymorphisms of DC-SIGN in relation to host genetic susceptibility to SARS infection | 804928 | 2005 |
| HKU 7550/05M | The role of L-SIGN (CD290L) in SARS coronavirus infection | 718957 | 2005 |
| 02040202 | Role of polymorphisms of the inflammatory response genes and DC-SIGNR in genetic susceptibility to SARS and other infections | 805000 | 2004 |
| N/A | Study of oncogenes in breast cancer | 0 | 1994 |
| N/A | The role of oncogenes in the development and progression of breast carcinoma | 554000 | 1995 |
| HKU 7520/05M | Gene-based and haplotype analysis of the estrogen receptor genes for breast cancer susceptibility | 718957 | 2005 |
| 21004458 | Infectious Diseases and Global Health: Genetic approach to the identification of host susceptibility factors and pathogen virulence determinants. Genetics of coronaviruses-associated acute respiratory disease | 718237 | 2005 |
| 03040792 | The functional role of ICAM3 polymorphism in genetic susceptibility to SARS infection | 797969 | 2005 |
| 210208 | HER2 FISH test to assess eligibility for transtuzumab (herceptin) in breast cancer patients applying for assistance from Samaritan Fund for treatment | 1208514 | 2010 |
| ITS/015/13 | Development of Antibody Specific to Splice Variant of NCOR2 for the Management of Breast Cancer | 899845 | 2013 |
| InP/318/13 | Development of Antibody Specific to Splice Variant of NCOR2 for the Management of Breast Cancer | 249425 | 2013 |
| InP/321/13 | Development of Antibody Specific to Splice Variant of NCOR2 for the Management of Breast Cancer | 211761 | 2013 |
| 213218 | HER2 Dual ISH test to assess eligibility for Trastuzumab (Herceptin) in breast cancer patients receiving treatment from public hospitals | 319640 | 2013 |
| N/A | Characterization of a Novel Splice Variant in Tamoxifen Resistant Breast Cancer | 1116180 | 2015 |
| 17113020 | Molecular mechanism of BQ323636.1, a novel splice variant of NCOR2 and its significance on treatment of estrogen receptor positive breast cancer. | 996285 | 2020 |
| N/A | Genetic polymorphism study of the immense response genes in relation to susceptibility, clinical outcome and treatment response of SARS | 75000 | 2003 |
| 04151826 | Hyperpolarization-activated cyclic nucleotide-gated channel 3 (HCN3) regulating apoptosis resistance, autophagy and cellular senescence in breast cancer: a novel potential anti-cancer target. | 1174577 | 2016 |
| ITS/069/16 | Testing Ivabradine on Patient Derived Xenografts: A Novel Potential Targeted Treatment for Breast Cancer | 1329925 | 2016 |
| 07182026 | The synergistic effect of Ivabradine and Olaparib on triple negative breast cancer | 1492110 | 2019 |
| 06171916 | Targeting androgen receptor in BQ323636.1 overexpressing ER+ breast cancer to overcome aromatase inhibitor resistance | 1230094 | 2018 |
| 17106824 | Ivabradine induces BRCAness in BRCA1/2 wild type triple-negative and ER-positive breast cancer, leading to PARP inhibitor sensitivity | 1558075 | 2024 |